IKK-β mediates hydrogen peroxide induced cell death through p85 S6K1

Cell Death and Differentiation

Volumn 20, Issue 2, 2013, Pages 248-258

  Jia, C H ^a   Li, M ^a   Liu, J ^b   Zhao, L ^a   Lin, J ^a   Lai, P L ^a   Zhou, X ^a   Zhang, Y ^a   Chen, Z G ^a   Li, H Y ^a   Liu, A L ^a   Yang, C L ^a   Gao, T M ^a   Jiang, Y ^c   Bai, X C ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

hydrogen peroxide; IKK ; mammalian target of rapamycin; S6K1

Indexed keywords

HYDROGEN PEROXIDE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; P85 S6 KINASE 1; PROTEIN MDM2; PROTEIN P53; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; HUMANS; HYDROGEN PEROXIDE; I-KAPPA B KINASE; MCF-7 CELLS; OXIDATIVE STRESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MDM2; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

MAMMALIA;

EID: 84872280035     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2012.115     Document Type: Article

References (48)

1. Weinberg F, Chandel NS. Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci 2009; 66: 3663-3673.
2. Veal EA, Day AM, Morgan BA. Hydrogen peroxide sensing and signaling. Mol Cell 2007; 26: 1-14.
3. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344-362.
4. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
5. Gloire G, Charlier E, Rahmouni S, Volanti C, Chariot A, Erneux C et al. Restoration of SHIP-1 activity in human leukemic cells modifies NF-kappaB activation pathway and cellular survival upon oxidative stress. Oncogene 2006; 25: 5485-5494.
6. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006; 72: 1493-1505.
7. Liu Q, Kou JP, Yu BY. Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-kappaB activation. Neurochem Int 2011; 58: 119-125.
8. Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S, Aggarwal BB. Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem 2003; 278: 24233-24241.
9. Korn SH, Wouters EF, Vos N, Janssen-Heininger YM. Cytokine-induced activation of nuclear factor-kappa B is inhibited by hydrogen peroxide through oxidative inactivation of IkappaB kinase. J Biol Chem 2001; 276: 35693-35700.
10. Fujioka S, Schmidt C, Sclabas GM, Li Z, Pelicano H, Peng B et al. Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. J Biol Chem 2004; 279: 27549-27559.
11. Jennewein C, Karl S, Baumann B, Micheau O, Debatin KM, Fulda S. Identification of a novel pro-apoptotic role of NF-kappaB in the regulation of TRAIL-and CD95-mediated apoptosis of glioblastoma cells. Oncogene 2011; 31: 1468-1474.
12. Ho JQ, Asagiri M, Hoffmann A, Ghosh G. NF-kappaB potentiates caspase independent hydrogen peroxide induced cell death. PLoS One 2011; 6: e16815.
13. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
14. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326: 140-144.
15. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40: 310-322.
16. Cheatham L, Monfar M, Chou MM, Blenis J. Structural and functional analysis of pp70S6k. Proc Natl Acad Sci USA 1995; 92: 11696-11700.
17. Reinhard C, Fernandez A, Lamb NJ, Thomas G. Nuclear localization of p85s6k: functional requirement for entry into S phase. EMBO J 1994; 13: 1557-1565.
18. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010; 11: 9-22.
19. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA et al. Phosphorylation and activation of p70s6k by PDK1. Science 1998; 279: 707-710.
20. Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Brenner DA. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology 1998; 27: 1285-1295.
21. Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 2009; 19: 404-413.
22. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007; 130: 440-455.
23. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-590.
24. Park KK, Liu K, Hu Y, Smith PD, Wang C, Cai B et al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 2008; 322: 963-966.
25. Lai KP, Leong WF, Chau JF, Jia D, Zeng L, Liu H et al. S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response. EMBO J 2010; 29: 2994-3006.
26. Kang YJ, Lu MK, Guan KL. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis. Cell Death Differ 2011; 18: 133-144.
27. Karassek S, Berghaus C, Schwarten M, Goemans CG, Ohse N, Kock G et al. Ras homolog enriched in brain (Rheb) enhances apoptotic signaling. J Biol Chem 2010; 285: 33979-33991.
28. Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006; 31: 342-348.
29. Li M, Zhao L, Liu J, Liu A, Jia C, Ma D et al. Multi-mechanisms are involved in reactive oxygen species regulation of mTORC1 signaling. Cell Signal 2010; 22: 1469-1476.
30. Dan HC, Adli M, Baldwin AS. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res 2007; 67: 6263-6269.
31. Dan HC, Baldwin AS. Differential involvement of IkappaB kinases alpha and beta in cytokine-and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol 2008; 180: 7582-7589.
32. Tsuchiya Y, Asano T, Nakayama K, Kato T Jr., Karin M, Kamata H. Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB activation. Mol Cell 2010; 39: 570-582.
33. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010; 24: 1580-1589.
34. Li Y, Wang Y, Kim E, Beemiller P, Wang CY, Swanson J et al. Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb. J Biol Chem 2007; 282: 35803-35813.
35. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98: 11598-11603.
36. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001; 3: 973-982.
37. Weber HO, Ludwig RL, Morrison D, Kotlyarov A, Gaestel M, Vousden KH. HDM2 phosphorylation by MAPKAP kinase 2. Oncogene 2005; 24: 1965-1972.
38. Malmlof M, Roudier E, Hogberg J, Stenius U. MEK-ERK-mediated phosphorylation of Mdm2 at Ser-166 in hepatocytes. Mdm2 is activated in response to inhibited Akt signaling. J Biol Chem 2007; 282: 2288-2296.
39. Hogan C, Hutchison C, Marcar L, Milne D, Saville M, Goodlad J et al. Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem 2008; 283: 18012-18023.
40. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006; 25: 6436-6446.
41. Inoki K, Guan KL. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum Mol Genet 2009; 18: R94-100.
42. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999; 253: 100-109.
43. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 2006; 3: 393-402.
44. Reinhard C, Thomas G, Kozma SC. A single gene encodes two isoforms of the p70 S6 kinase: activation upon mitogenic stimulation. Proc Natl Acad Sci USA 1992; 89: 4052-4056.
45. Jaafar R, Zeiller C, Pirola L, Di Grazia A, Naro F, Vidal H et al. Phospholipase D regulates myogenic differentiation through the activation of both mTORC1 and mTORC2 complexes. J Biol Chem 2011; 286: 22609-22621.
46. Kim D, Akcakanat A, Singh G, Sharma C, Meric-Bernstam F. Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors 2009; 27: 12-21.
47. Rosner M, Hengstschlager M. Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR. Oncogene 2011; 30: 4509-4522.
48. Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007; 318: 977-980.